Health-Related Quality of Life in Patients with HR+/HER2− Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial
Authors:
- Peter A. FaschingPeter A. Fasching
- Dennis SlamonDSDennis Slamon
- Zbigniew NoweckiZNZbigniew Nowecki
- Bozena Kukielka-BudnyBKBozena Kukielka-Budny
- Daniil StroyakovskiyDSDaniil Stroyakovskiy
- Denise A. YardleyDYDenise A. Yardley
- Chiun-Sheng HuangCHChiun-Sheng Huang
- Arlene ChanACArlene Chan
- Stephen ChiaStephen Chia
- Miguel MartínMMMiguel Martín
- Hope S. RugoHRHope S. Rugo
- Sherene LoiSLSherene Loi
Open Access
- 28 February 2025
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 31 (9) , 1625-1635
Abstract
Purpose: The phase III NATALEE trial reported a statistically significant invasive disease-free survival benefit with ribociclib plus nonsteroidal aromatase inhibitor (NSAI) versus an NSAI alone in stage II/III hormone receptor–positive, HER2-negative (HR+/HER2−) early breast cancer. In this study, we report health-related quality of life (HRQOL) data from NATALEE. Patients and Methods: Patients were randomized to receive ribociclib plus NSAI or NSAI alone. Patient-reported outcome scores [European Organisation for Research and Treatment of Cancer core quality of life questionnaire global health status and physical, social, and emotional functioning domains; the supplementary European Organisation for Research and Treatment of Cancer breast cancer–specific QOL questionnaire breast symptoms scale; health on a visual analog scale of the generic EuroQOL 5-level instrument; and the Hospital Anxiety and Depression Scale] were assessed. The prespecified primary HRQOL endpoint was physical functioning. Mean scores and time-categorical and prespecified linear-time repeated-measure models were used to evaluate HRQOL changes during treatment. Results: HRQOL was evaluated in all patients in the ribociclib plus NSAI (n = 2,549) and NSAI alone (n = 2,552) arms. Compliance was high in both arms (≈93%–97%). Mean scores did not differ meaningfully from baseline for any analyzed domain. Likewise, neither a meaningful change from baseline (in either treatment arm) nor a difference between arms was observed during treatment in the time-categorical, model-adjusted mean scores for any HRQOL domains—using published thresholds for interpreting longitudinal and between-group differences, with all values being within 0.5 SD of their baseline values. Linear-time regression analysis confirmed these findings. Conclusions: These analyses of NATALEE show that adding adjuvant ribociclib to an NSAI does not negatively affect HRQOL in patients with HR+/HER2− early breast cancer.Keywords
All Related Versions
Funding Information
- Novartis Pharmaceuticals Corporation
This publication has 59 references indexed in Scilit:
- The Symptom Cluster of Fatigue, Pain, Anxiety, and Depression and the Effect on the Quality of Life of Women Receiving Treatment for Breast Cancer: A Multicenter StudyOncology Nursing Forum, 2009
- What do predict anxiety and depression in breast cancer patients? A follow-up studySocial Psychiatry and Psychiatric Epidemiology, 2009
- Physical Performance Limitations and Participation Restrictions Among Cancer Survivors: A Population-Based StudyAnnals of Epidemiology, 2006
- Quality of Life at the End of Primary Treatment of Breast Cancer: First Results From the Moving Beyond Cancer Randomized TrialJNCI: Journal of the National Cancer Institute, 2004
- Interpretation of Changes in Health-related Quality of LifeMedical Care, 2003
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001
- Physical exercise and quality of life following cancer diagnosis: A literature reviewAnnals of Behavioral Medicine, 1999
- A Canadian Survey of Cancer Patients’ ExperiencesJournal of Pain and Symptom Management, 1998
- The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study.Journal of Clinical Oncology, 1996
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983